Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
“Approval of an immediate-use intranasal diazepam treatment that can be given at any time—even while a child is actively seizing—in this young age group is an important advance for the epilepsy community.”
The FDA approved dupilumab as the first targeted therapy for chronic spontaneous urticaria in patients aged 12 years and older uncontrolled on antihistamines.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.
The FDA has approved a tablet formulation of maralixibat (LIVMARLI) for treating cholestatic pruritus in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.
Dexcom G7 15 Day receives FDA clearance, offering adults with diabetes the longest lasting and most accurate continuous glucose monitoring system to date.